These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 22349253)

  • 1. Effect of one-month treatment with vaginal promestriene on serum estrone sulfate levels in cancer patients: a pilot study.
    Del Pup L; Postruznik D; Corona G
    Maturitas; 2012 May; 72(1):93-4. PubMed ID: 22349253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of vaginal dryness and dyspareunia in estrogen sensitive cancer patients.
    Del Pup L
    Gynecol Endocrinol; 2012 Sep; 28(9):740-5. PubMed ID: 22409649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Topical hormonal treatment and urogenital atrophy].
    Sitruk-Ware R; Thomas JL
    Praxis (Bern 1994); 1997 Aug; 86(33):1245-8. PubMed ID: 9381009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of transdermal and vaginal estrogen therapy on markers of postmenopausal estrogen status.
    Gupta P; Ozel B; Stanczyk FZ; Felix JC; Mishell DR
    Menopause; 2008; 15(1):94-7. PubMed ID: 17882008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative uterine effects on ovariectomized rats after repeated treatment with different vaginal estrogen formulations.
    López-Belmonte J; Nieto C; Estevez J; Delgado JL; del Prado JM
    Maturitas; 2012 Aug; 72(4):353-8. PubMed ID: 22683083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimized estradiol absorption with ultra-low-dose 10 microg 17beta-estradiol vaginal tablets.
    Eugster-Hausmann M; Waitzinger J; Lehnick D
    Climacteric; 2010 Jun; 13(3):219-27. PubMed ID: 20423242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of one-week treatment with vaginal estrogen preparations on serum estrogen levels in postmenopausal women.
    Labrie F; Cusan L; Gomez JL; Côté I; Bérubé R; Bélanger P; Martel C; Labrie C
    Menopause; 2009; 16(1):30-6. PubMed ID: 18820592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaginal estrogens for the treatment of dyspareunia.
    Krychman ML
    J Sex Med; 2011 Mar; 8(3):666-74. PubMed ID: 21091878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women.
    Kagan R; Williams RS; Pan K; Mirkin S; Pickar JH
    Menopause; 2010 Mar; 17(2):281-9. PubMed ID: 19779382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of usefulness of estradiol vaginal tablets and estriol vagitories for treatment of vaginal atrophy.
    Dugal R; Hesla K; Sørdal T; Aase KH; Lilleeidet O; Wickstrøm E
    Acta Obstet Gynecol Scand; 2000 Apr; 79(4):293-7. PubMed ID: 10746845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topical estrogen therapy in the management of postmenopausal vaginal atrophy: an up-to-date overview.
    Al-Baghdadi O; Ewies AA
    Climacteric; 2009 Apr; 12(2):91-105. PubMed ID: 19117185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose 17-β-estradiol cream for vaginal atrophy in a cohort without prolapse: Serum levels and vaginal response including tissue biomarkers associated with tissue remodeling.
    Illston JD; Wheeler TL; Parker CR; Conner MG; Burgio KL; Goode PS; Richter HE
    Maturitas; 2015 Aug; 81(4):475-9. PubMed ID: 26115591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promestriene, a specific topic estrogen. Review of 40 years of vaginal atrophy treatment: is it safe even in cancer patients?
    Del Pup L; Di Francia R; Cavaliere C; Facchini G; Giorda G; De Paoli P; Berretta M
    Anticancer Drugs; 2013 Nov; 24(10):989-98. PubMed ID: 24080714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of postmenopausal vaginal atrophy with 10-μg estradiol vaginal tablets.
    Panay N; Maamari R
    Menopause Int; 2012 Mar; 18(1):15-9. PubMed ID: 22393176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Twice-weekly synthetic conjugated estrogens vaginal cream for the treatment of vaginal atrophy.
    Freedman M; Kaunitz AM; Reape KZ; Hait H; Shu H
    Menopause; 2009; 16(4):735-41. PubMed ID: 19252451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Safety of promestriene capsule used in postmenopausal atrophic vaginitis].
    Sun AJ; Lin SQ; Jing LH; Wang ZY; Ye JL; Zhang Y
    Zhonghua Fu Chan Ke Za Zhi; 2009 Aug; 44(8):593-6. PubMed ID: 20003787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet.
    Weisberg E; Ayton R; Darling G; Farrell E; Murkies A; O'Neill S; Kirkegard Y; Fraser IS
    Climacteric; 2005 Mar; 8(1):83-92. PubMed ID: 15804736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TX-004HR vaginal estradiol has negligible to very low systemic absorption of estradiol.
    Archer DF; Constantine GD; Simon JA; Kushner H; Mayer P; Bernick B; Graham S; Mirkin S;
    Menopause; 2017 May; 24(5):510-516. PubMed ID: 28002201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Managing postmenopausal vaginal atrophy. Vaginal dryness is one of the most irritating symptoms of menopause. Here are some ways to relieve it.
    Harv Womens Health Watch; 2010 Mar; 17(7):4-5. PubMed ID: 20480969
    [No Abstract]   [Full Text] [Related]  

  • 20. Associations between improvement in genitourinary symptoms of menopause and changes in the vaginal ecosystem.
    Mitchell CM; Srinivasan S; Plantinga A; Wu MC; Reed SD; Guthrie KA; LaCroix AZ; Fiedler T; Munch M; Liu C; Hoffman NG; Blair IA; Newton K; Freeman EW; Joffe H; Cohen L; Fredricks DN
    Menopause; 2018 May; 25(5):500-507. PubMed ID: 29206774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.